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Abstract 
Progressive multifocal leukoencephalopathy (PML) caused by reactivation of the JC virus 
(JCV), a human polyomavirus, occurs in autoimmune disorders, most frequently in systemic 
lupus erythematosus (SLE). We describe a HIV-negative 34-year-old female with SLE who had 
been treated with immunosuppressant therapy (IST; steroids and azathioprine) since 2004. In 
2011, she developed decreased sensation and weakness of the right hand, followed by verti-
go and gait instability. The diagnosis of PML was made on the basis of brain MRI findings 
(posterior fossa lesions) and JCV isolation from the cerebrospinal fluid (700 copies/ml). IST 
was immediately discontinued. Cidofovir, mirtazapine, mefloquine and cycles of cytarabine 
were sequentially added, but there was progressive deterioration with a fatal outcome 1 year 
after disease onset. This report discusses current therapeutic choices for PML and the im-
portance of early infection screening when SLE patients present with neurological symptoms. 
In the light of recent reports of PML in SLE patients treated with rituximab or belimumab, we 
highlight that other IST may just as well be implicated. We conclude that severe lymphopenia 
was most likely responsible for JCV reactivation in this patient and discuss how effective 
management of lymphopenia in SLE and PML therapy remains an unmet need. 
 © 2016 The Author(s) 
 Published by S. Karger AG, Basel 
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Introduction 
Progressive multifocal leukoencephalopathy (PML) is a rare and devastating demye-
linating disease of the central nervous system. The disease is caused by reactivation of a 
polyomavirus, the JC virus (JCV), that was first described as a rare complication of chemo-
therapy in patients with lymphoproliferative disorders [1]. The dramatic increase of PML 
incidence during the AIDS epidemic in the 1980s and the occurrence of PML in patients with 
idiopathic CD4+ lymphopenia [2] pointed to the importance of CD4+ T cells in the immune 
control of JCV infections. Asymptomatic primary JCV infection actually occurs in up to 80% 
of the individuals, the virus remaining latent in lymphocytes and glial cells. Both T- and B-
cell effector functions are required to prevent viral reactivation [3]. In autoimmune disor-
ders, PML occurs mostly in patients with systemic lupus erythematosus (SLE) [4]. Of note, 
most SLE patients who develop PML have been either subjected or are concomitantly under 
immunosuppressant therapy (IST), with a diverse combination of therapeutic regimens that 
causes generalized immunosuppression. Steroids, azathioprine, mycophenolate mofetil, 
cyclophosphamide, methotrexate, thalidomide, dapsone and other specifically targeted ther-
apies, such as rituximab or belimumab, are the treatments usually prescribed [5]. While the 
main cause of PML in SLE patients is likely to be therapy-related immunodeficiency, there is 
no correlation between the intensity of IST and PML development in SLE patients, suggest-
ing that alternative mechanisms of JCV reactivation may exist in some patients [6]. Most case 
reports on SLE patients with PML lack data on total lymphocytes or lymphocyte subsets 
despite the fact that when reported, CD4+ T-cell counts are severely reduced [7]. Here, we 
report on a patient with SLE and persistent lymphopenia who developed PML. 
Case Presentation 
A young HIV-negative Portuguese female was diagnosed with SLE at the age of 12 on the 
basis of polyarthralgias, pneumonitis, high fever and autoantibody reactivities including 
antinuclear antibody (ANA) and anti-double-stranded (ds) DNA. Additional cumulative fea-
tures relating to SLE consisted of photosensitivity, Jaccoud arthropathy, alopecia and fatigue, 
and ongoing positivity for anti-Smith-/ribonucleoprotein, antinucleosome and antihistone, 
quantified at 3+, with persistent absence of anti-SSA and anti-SSB (Euroimmun). Case rec-
ords show that in 2004, for a period of 7 months, the anti-dsDNA antibody titer fluctuated 
between 1/10 and 1/30 (positive values by Crithidia luciliae immunofluorescence assay), 
after which time the test became negative. Thereafter, her illness was characterized by in-
termittent arthralgia of the small joints of the hands, knees and ankles. There was persistent 
hypocomplementemia and polyclonal hypergammaglobulinemia, with a high IgG (peak value 
2,390 mg/dl; upper limit of normal 1,400), normal IgM and IgA concentrations. From 2004 
to 2011, her white blood and total lymphocyte counts ranged from 2,300 to 3,900 × 106/l 
and from 600 to 1,400 × 106/l, respectively, with mean counts of 3,000 and 1,000 × 106/l, 
respectively. Lymphocyte phenotyping by flow cytometry was not performed during this 
time. The hemoglobin concentration and platelet counts were normal. She was not taking 
hydroxychloroquine and had been started on azathioprine 50 mg/day and deflazacort 6 
mg/day, which were continued from 2004 to February 2012. At her last regular follow-up 
visit in December 2011 she complained of decreased sensation and weakness of the right 
hand. An electromyography was planned. There were no clinical signs of lupus disease activ-
ity with an ANA titer of 1/320, negative anti-dsDNA, normal C3 (95.4 mg/dl), slightly re-
duced C4 of 8.25 mg/dl (normal values 10–34) and normal urinary sediment. 
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In February 2012, at the age of 34, she complained of nausea, vertigo, limb ataxia and 
gait instability. At first, only slight ataxia of the right arm was noted. She was admitted to 
hospital and while waiting for a cerebral MRI, her symptoms rapidly deteriorated with epi-
sodes of vomiting and worsened limb ataxia, which became bilateral. Gadolinium-enhanced 
MRI of the brain revealed patchy high-signal intensity lesions on T2-weighted images in the 
right cerebellar peduncle without diffusion restriction (fig. 1). MRI angiography and a con-
ventional cerebral angiogram showed no abnormalities of the vascular system and no signs 
of vasculitis. The total lymphocyte count was 800 × 106/l; there was no anemia or evidence 
of renal or hepatic dysfunction, and ANA and anti-dsDNA were positive, with a low concen-
tration of complement components C3 and C4. Blood serology was negative for herpes sim-
plex virus, cytomegalovirus, Epstein-Barr virus, enterovirus, varicella-zoster virus, human T-
lymphotropic virus types 1 and 2, HIV, lyme disease and syphilis. Cerebrospinal fluid exami-
nation (CSF) revealed: (1) normal cell counts, protein, glucose, lactate, and immunoglobulin 
index, no oligoclonal bands and absent borrelia antibodies; (2) negative Gram stain, negative 
cultures for bacteria and negative microbiologic PCR for mycobacteria, herpes simplex virus, 
varicella-zoster virus, cytomegalovirus, Epstein-Barr virus, human T-lymphotropic virus 
types 1 and 2, Cryptococcus spp. and other fungi; (3) negative angiotensin-converting en-
zyme and glial fibrillary acidic protein; (4) negative paraneoplastic and inflammatory anti-
body screen (anti-Hu, Yo, Ri and Purkinje cells, NMDA receptor, MA-2), MBP, MOG and neu-
romyelitis optica, and (5) slight increase in polygonal IgG and neurofilament. CSF PCR was 
positive for JCV (700 copies/ml), which, together with the clinical data and MRI findings, 
clinched the diagnosis of PML. 
Steroids and azathioprine were discontinued. Treatment with cidofovir 5 mg/kg was 
started, the first 3 treatments 4 days apart and then every second week, to which mirtazap-
ine 45 mg daily was added. Despite these therapeutic measures, there was clinical deteriora-
tion with abnormal saccadic eye movements and failure of fixation, scanning dysarthria and 
more prominent gait ataxia, requiring gait assistance to prevent falls. Two weeks later, a new 
MRI showed progress of signal abnormality in the cerebellum and further extension now 
involving the brain stem and thalami. After 2 months, mirtazapine was reduced to 30 
mg/day to avoid excess sedation, and mefloquine 250 mg/day once a week was started. Clin-
ical deterioration as well as progression of MRI signal intensity in the pons and periventricu-
lar demyelination continued at 3 months after the onset of her symptoms. The patient expe-
rienced additional paresthesia on the left side of her face and swallowing difficulties. Cytara-
bine was added to cidofovir based on previously reported successful treatment results [8]. 
Thereafter, her clinical state deteriorated with progressive neurological dysfunction, 
lethargy and confusion. The patient was bedridden and no longer able to communicate due 
to severe dysarthria. She was suffering from constant nausea, vomiting, diplopia, nystagmus, 
dysphagia, hemiparesthesia, right-sided hemiparesis and severe limb, gait and truncal ataxia. 
She also developed severe depression with mood changes, crying outbursts, despair, insom-
nia and loss of appetite. At 5 months after hospital admission, the MRI showed further dis-
ease progression in the pons (fig. 2). During treatment, CD4+ levels and the CD4/CD8 ratio 
ranged between 262 and 381 × 106/l and 0.7 and 1.1 × 106/l, respectively. A slight initial 
decrease in JCV copies in the CSF was followed by a further increase to 1,400 and 2 months 
later to 2,500 copies/ml, after which there was a continuous increase up to 3,900 copies/ml, 
the latter measured at 6 months after hospital admission. She was then transferred to Portu-
gal where treatment with cidofovir and cytarabine were discontinued as she suffered seri-
ous recurrent infections. At 12 months after the initial diagnosis, a new MRI showed bilateral 
periventricular high-signal intensity lesions (fig. 3), and the patient died in a persistent vege-
tative state 1 year after the start of her disease. 
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Discussion 
SLE is an autoimmune disease of unknown etiology with heterogeneous manifestations 
involving several organ systems, including the brain. Patients with neuropsychiatric lupus 
may present a wide spectrum of syndromes such as headache, seizures, aseptic meningitis, 
stroke, psychosis, cranial neuropathy, demyelinating syndromes, movement and cognitive 
disorders [9]. Medication side effects, metabolic abnormalities and particularly infections 
can be a major cause of SLE central nervous system syndromes [9] and were therefore inves-
tigated promptly in the diagnostic workup. Our patient fulfilled the current diagnostic crite-
ria for PML, consisting of neurological features, typical imaging and detection of JCV in the 
CSF by PCR [10]. 
Neurological features vary widely in PML patients. Visual disturbances, motor weak-
ness, altered mental state and sensory deficit remain the most common ones, whereas symp-
toms due to mass effect or epilepsy are quite rare [11]. MRI is the most sensitive imaging 
method for the investigation of suspected PML, typical lesions appearing hyperintense on 
fluid-attenuated inversion recovery and T2-weighted sequences [3]. In our patient, initial 
suspicion of peripheral nerve entrapment delayed the diagnostic workup, as a consequence 
of which therapy was instituted at a late stage, the latter probably contributing to refractori-
ness to therapy, with a relentless clinical deterioration reflected by increasing MRI lesions, 
leading to death. 
Increased susceptibility to severe bacterial infections has been described in association 
with lymphopenia defined by <1,000 lymphocytes ×106/l [12]. Lymphopenia in SLE is usual-
ly regarded as a disease manifestation, targeting lymphocytes or their precursors as an ex-
pected side effect of IST. However, interestingly, lymphopenia has been observed in up to 
70% of the untreated patients at disease onset, suggesting that it may be a promoter rather 
than a consequence of the SLE disease process [13]. There are no current recommendations 
for the investigation and treatment of SLE patients with severe or persistent lymphopenia, in 
the absence or presence of IST. As a result, lymphopenia is frequently ignored in clinical 
practice when we believe that instead it should constitute a major clinical concern. Current 
recommendations for dealing with lymphopenia are poor. These essentially support main-
taining a lymphocyte count >1,000 lymphocytes ×106/l, exclusion of infections and lym-
phoproliferative disease, and principally advocate adjustment of IST without proposing re-
placement therapies [14]. Our patient presented with very low CD4+ T-cell counts and a low 
CD4/CD8 T-cell ratio, which most likely contributed to the JCV reactivation. 
Treatment of SLE patients with PML should eliminate the virus and increase lymphocyte 
counts without aggravating any SLE manifestations. Highly active antiretroviral therapy has 
reduced mortality rates in HIV-positive patients with PML [3]. However, the treatment of 
non-HIV PML remains a challenge. Classical options have been based on immunomodulation 
and antiviral therapy. Cidofovir, an antiviral nucleotide analogue, showed some efficacy in 
the treatment of HIV-positive patients with PML but it has been unsuccessful in HIV-negative 
patients [2]. Cytarabine, a chemotherapy agent (nucleoside arabinoside), has been one of the 
most frequently used drugs despite commonly encountered adverse effects of nausea and 
bone marrow toxicity, but its use remains controversial. A randomized controlled trial of 
cytarabine in 57 patients did not show any efficacy in treating HIV-positive subjects with 
PML, whereas another study reported positive clinical efficacy results in 7/19 (36%) of the 
patients [3]. We used cidofovir and cytarabine based on a successful report [8]. Mirtazapine 
was added to her therapy because in vitro studies have suggested a role for the 5-HT2a re-
ceptors acting as the receptor for JCV in glial cells in the brain [3]. We added mefloquine, a 
widely used antimalarial drug that showed some efficacy in inhibiting the JCV infection be-
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cause of in vitro data as well as clinical improvement in patients with PML [3]. A clinical case 
study with a combination of the antiviral agent CMX001, an oral formulation of cidofovir and 
recombinant human interleukin-7 (CYT107), an inducer of CD4+ and CD8+ T cells, reported 
successful treatment in PML [3]. Unfortunately, these investigational drugs were not availa-
ble at the time our patient required treatment. 
Current guidelines on the treatment of SLE suggest that antimalarials may be of benefit 
in SLE patients without major organ manifestations [15]. We were unable to understand 
why the patient was not on hydroxychloroquine, which may have provided symptomatic 
control for the arthralgia and spared her from IST. JC polyomavirus screening for PML risk 
stratification in patients under IST should perhaps be extended to SLE patients with 
longstanding lymphopenia in order to prevent viral reactivation in this setting. The present 
case study highlights several aspects in SLE patient management. JCV infection should be 
considered at the onset of neuropsychiatric symptoms, total lymphocyte and lymphocyte 
subset counts should be performed at regular intervals and, most importantly, IST leading to 
lymphopenia should be avoided for as long as possible. 
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Fig. 1. MRI at the onset of neurological symptoms. Axial T2-weighted fluid-attenuated inversion recovery 
(FLAIR) shows patchy high-signal intensity PML lesions in the right cerebellar peduncle. 
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Fig. 2. MRI 5 months later. T2-weighted FLAIR shows a progress of high-signal intensity in the pons. 
 
 
 
Fig. 3. MRI at the terminal stage of the disease. Axial T2-weighted MRI shows periventricular high-signal 
intensity. 
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